High-dose dexamethasone regulates microglial polarization via the GR/JAK1/STAT3 signaling pathway after traumatic brain injury

Although microglial polarization and neuroinflammation are crucial cellular responses after traumatic brain injury,the fundamental regulatory and functional mechanisms remain insufficiently understood.As potent anti-inflammato ry agents,the use of glucoco rticoids in traumatic brain injury is still controversial,and their regulatory effects on microglial polarization are not yet known.In the present study,we sought to determine whether exacerbation of traumatic brain injury caused by high-dose dexamethasone is related to its regulatory effects on microglial polarization and its mechanisms of action.In vitro cultured BV2 cells and primary microglia and a controlled cortical impact mouse model were used to investigate the effects of dexamethasone on microglial polarization.Lipopolysaccharide,dexamethasone,RU486(a glucocorticoid receptor antagonist),and ruxolitinib(a Janus kinase 1 antagonist)were administered.RNA-sequencing data obtained from a C57BL/6 mouse model of traumatic brain injury were used to identify potential targets of dexamethasone.The Morris water maze,quantitative reverse transcription-polymerase chain reaction,western blotting,immunofluorescence and confocal microscopy analysis,and TUNEL,Nissl,and Golgi staining were performed to investigate our hypothesis.High-throughput sequencing results showed that arginase 1,a marker of M2 microglia,was significantly downregulated in the dexamethasone group compared with the traumatic brain injury group at3 days post-traumatic brain injury.Thus dexamethasone inhibited M1 and M2 microglia,with a more pronounced inhibitory effect on M2microglia in vitro and in vivo.Glucocorticoid receptor plays an indispensable role in microglial polarization after dexamethasone treatment following traumatic brain injury.Additionally,glucocorticoid receptor activation increased the number of apoptotic cells and neuronal death,and also decreased the density of dendritic spines.A possible downstream receptor signaling mechanism is the GR/JAK1/STAT3 pathway.Overactivation of glucocorticoid receptor by high-dose dexamethasone reduced the expression of M2 microglia,which plays an antiinflammatory role.In contrast,inhibiting the activation of glucocorticoid receptor reduced the number of apoptotic glia and neurons and decreased the loss of dendritic spines after traumatic brain injury.Dexamethasone may exe rt its neurotoxic effects by inhibiting M2 microglia through the GR/JAK1/STAT3 signaling pathway.

Dexamethasone in coronavirus disease 2019 care:Dosage and utilization insights

Coronavirus disease 2019(COVID-19)is a contagious disease caused by severe acute respiratory syndrome coronavirus 2.It was declared a global pandemic on March 11,2020,by the World Health Organization.An excessive inflammatory response is a severe respiratory manifestation of COVID-19,which becomes predominant in later stages.Due to its immunosuppressive and anti-inflammatory properties,dexamethasone is the first systemic glucocorticoid to treat severe COVID-19 patients.This editorial reviews the efficacy and safety of highdose vs low-dose dexamethasone in patients with COVID-19.Findings indicate that using low-dose dexamethasone is beneficial and emphasize the need for additional research on the use of high-dose dexamethasone.While the study provides a robust evidence base,it is limited by the lack of long-term data,focus on specific outcomes and heterogeneity of the included studies.Future research should focus on the long-term effects of dexamethasone and its impact across varying disease severities and patient populations to refine treatment strategies and improve patient care.

Revisiting dexamethasone dosage in COVID-19 management

The ongoing coronavirus disease 2019(COVID-19)pandemic has necessitated rapid advancements in therapeutic strategies,with dexamethasone emerging as a key treatment for severe cases.This editorial discusses the systematic review conducted by Sethi et al,published in the World Journal of Virology.The review critically examines the efficacy and safety of varying dosages of dexamethasone in severe COVID-19 patients,providing a comprehensive meta-analysis that underscores the current clinical recommendations favoring a low-dose regimen.Despite these findings,the review highlights the potential benefits of tailored dosages for specific patient subgroups,suggesting a need for personalized treatment approaches.This editorial expands on the implications of these findings,advocating for the integration of evolving clinical data into treatment protocols and calling for further research into patient-specific responses to therapy.It emphasizes the importance of adaptability and precision in pandemic response,urging the medical community to consider both the robustness of existing evidence and the potential for innovative approaches to enhance patient outcomes in the face of global health challenges.

Unveiling osteoprotective potential of biologically active naringenin in rats with dexamethasone-induced osteoporosis

Objective To investigate the protective effects of naringenin(NRG)against dexamethasone(DEX)-induced osteoporosis(OP)in rats.Methods Molecular docking of NRG was done with AutoDock Vina 1.2.0 software.Forty-eight female Wistar rats were randomly divided into six groups(n=8 each):normal control(NC),DEX(7 mg/kg,i.m.),NRG-low(NRG-L;25 mg/kg,i.g.),NRG-medium(NRG-M;50 mg/kg,i.g.),NRG-high(NRG-H;100 mg/kg,i.g.),and alendronate(ALN;0.25 mg/d,i.g.)groups.OP was induced by administering DEX once a week for five weeks in all groups except NC group.Begining in the third week after the initial DEX administration,the rats in NRG-L,NRG-M,NRG-H,and ALN groups received the corresponding treatments daily for three weeks,while NC and DEX groups received no additional treatment.Serum samples were collected at the end of the experiment for biochemical,bone turnover,antioxidant,lipid profile,and inflammatory cytokine analyses.Femur bones underwent physical parameter testing and histopathological examination.Results The molecular docking results illustrated that NRG docked with calcitonin(CT),lowdensity lipoprotein(LDL),bone morphogenetic protein(BMP),vascular endothelial growth factor(VEGF)receptor,forkhead transcription factors,and osteoprogenitor cells showed good binding energy.In rats administered with 25,50,and 100 mg/kg NRG,there was a significant enhancement in serum biochemical indices,characterized by a reduction in tartrate-resistant acid phosphatase(TRAP),parathyroid hormone(PTH),and an elevation in osteocalcin(OC)and CT levels(P<0.05,P<0.01,and P<0.001,respectively).Despite no significant changes in thickness,weight,and length(P>0.05),there was a marked increase in bone mineral density(BMD)(P<0.01,P<0.001,and P<0.001,respectively).Antioxidant enzyme markers showed significant upregulation,with higher glutathione,superoxide dismutase,and catalase,and a concurrent decrease in malondialdehyde(MDA)(P<0.05,P<0.01,and P<0.001,respectively).The lipid profile also improved significantly,with lower cholesterol(CH),triglycerides(TG),and low-density lipoprotein(LDL)levels,and an increase in high-density lipoprotein(HDL)level(P<0.05,P<0.01,and P<0.001,respectively).Inflammatory cytokine levels were reduced,as evidenced by decreases in tumor necrosis factor(TNF),interleukin(IL)-6,and IL-1β(P<0.05,P<0.01,and P<0.001,respectively).Furthermore,histological alterations revealed obvious improvements,and the body weight of rats treated with NRG showed an increase compared with DEX group.Conclusion These findings imply that NRG exhibited a protective effect against DEX-induced OP in rats as it promotes the bone formation process by increasing the number of bone turnover markers including OC and CT,and restoring of antioxidant status,lipid metabolism,and inflammatory markers.

Enhancing global hepatocellular carcinoma management:Bridging Eastern and Western perspectives on dexamethasone and Nacetylcysteine before transarterial chemoembolization

This article explores the integration of Eastern and Western perspectives on the use of dexamethasone and N-acetylcysteine as premedications in transarterial chemoembolization for hepatocellular carcinoma(HCC).By examining key concerns raised by Western researchers,particularly regarding the different etiologies of liver cirrhosis,and contrasting them with robust clinical data from Asia,this article highlights the necessity for region-specific research and proposes future directions for global HCC management.

Dexamethasone implant in naive versus refractory patients with diabetic macular edema:a Meta-analysis

AIM:To evaluate the efficacy and safety of the intravitreal dexamethasone implant in naive and refractory patients with diabetic macular edema(DME).METHODS:PubMed,Embase,Web of Science,and Medline databases were searched.The main outcomes were best-corrected visual acuity(BCVA)and central retinal thickness(CRT).The secondary outcomes included mean number of injections,intraoperative or postoperative complications including intraocular pressure(IOP)elevation and cataract.RESULTS:Ten comparative studies involving a total of 1000 DME eyes including 402 naive eyes and 598 refractory eyes were selected.The postoperative BCVA in the naive group was significantly better than in the refractory group[mean difference(MD)-0.11,95% confidence interval(CI)-0.17 to-0.05,P=0.0003;MD 8.69,95%CI 5.08 to 12.30,P<0.00001].Additionally,the naive group got greater improvement of BCVA change as well as more gains of BCVA letters than the refractory group[MD 7.71,95%CI 2.02 to 13.40,P=0.008;odds ratio(OR)2.99,95%CI 2.05 to 4.37,P<0.00001].The subgroup analysis revealed that the naive group had significantly higher BCVA gains of≥5,≥10,and≥15 letters compared to the refractory group(P=0.002,0.0001,0.003,respectively).No significant difference was detected between the two groups in either postoperative CRT(MD-22.36,95%CI-46.39 to 1.66,P=0.07)or the overall mean number of injections(MD-0.08,95%CI-0.38 to 0.22,P=0.61).Intraoperative and postoperative complications including the elevation of IOP(OR 0.47,95%CI 0.20 to 1.13,P=0.09)and cataract(OR 1.78,95%CI 0.97 to 3.24,P=0.06)showed no significant differences between the two groups during the follow-up time.CONCLUSION:Intravitreal dexamethasone implants for DME can improve anatomical and functional outcomes in both naive and refractory eyes and have a well-acceptable safety profile.Moreover,naive eyes maintain better visual outcomes than refractory eyes.It provides further evidence of better visual response when used for naive eyes as firstline therapy.

Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion

AIM:To evaluate the efficacy,timing of retreatment and safety of dexamethasone(DEX)implant on macular edema(ME)secondary to diabetic retinopathy(DME)and retinal vein occlusion(RVO-ME)patients who were refractory to anti-vascular endothelial growth factor(VEGF)treatment.METHODS:This retrospective study included 37 eyes received at least one DEX implant treatment for DME or RVO-ME between January 1,2019,and January 1,2023.These refractory DME and RVO-ME cases received at least 5 anti-VEGF injections and failure to gain more than 5 letters or a significant reduction in central retinal thickness(CRT).The best corrected visual acuity(BCVA)and CRT were measured at baseline,and at 1,3,4 and 6mo post-DEX implant injection.Adverse events such as elevated intraocular pressure(IOP)and cataract were recorded.RESULTS:For RVO cases(n=22),there was a significant increase in BCVA from 0.27±0.19 to 0.35±0.20 at 6mo post-DEX injection(P<0.05)and CRT decreased from 472.1±90.6 to 240.5±39.0μm at 6mo(P<0.0001).DME cases(n=15)experienced an improvement in BCVA from 0.26±0.15 to 0.43±0.20 at 6mo post-DEX implant injection(P=0.0098),with CRT reducing from 445.7±55.7 to 271.7±34.1μm at 6mo(P<0.0001).Elevated IOP occurred in 45.9% of patients but was well-controlled with topical medications.No cases of cataract or other adverse events were reported.CONCLUSION:DEX implants effectively improve BCVA and reduce CRT in refractory DME and RVO-ME.Further research with larger cohorts and longer follow-up periods is needed to confirm these findings and assess long-term outcomes.

Optical Coherence Tomography (OCT) Feature Identifying Niche for Dexamethasone (FIND) Intravitreal Implant in the Treatment of Anti-VEGF Slow Responders with Diabetic Macular Edema

This paper raises the question if intravitreal dexamethasone implant deserves to be utilized more effectively in a select subset of eyes with diabetic macular edema (DME). If so, what is the OCT morphology of such eyes? A retrospective consecutive case series is employed to answer these questions. Twenty consecutive eyes were studied: ten that have been treated with intravitreal anti-VEGF (Group A) injections and ten which have been treated with the steroidal implant (Group O) because they failed or were slow to respond to multiple injections of anti-VEGF medications. Specifically, 1) macular edema in the eyes were categorized for the type of OCT morphology and 2) their response to the respective treatments in terms of the resolution of the OCT morphology was determined. Results show that the OCT morphology of eyes that were in Group O predominantly (7/10) had the feature of posterior retinal leakage (subretinal fluid and large outer retinal cysts);this feature was rare in Group A (2/10). Further, each of these eyes (7/7) in Group O had a complete resolution of the macular edema after a single treatment with the dexamethasone intravitreal implant whereas neither eye with this feature (0/2) responded to the (anti-VEGF) treatment in Group A. This leads to the conclusion that there exists an OCT Feature that Identifies a Niche for Dexamethasone Intravitreal implant (FIND) in the treatment of anti-VEGF slow responders in DME. The clinical significance of the study is that selecting eyes with a priori FIND morphology on the OCT for treatment with dexamethasone implant prior to, or at the outset of, a series of anti-VEGF treatment may resolve DME promptly and lower the treatment burden for patients and cost to society.

Treatment Efficacy and Safety of Bortezomib Combined with Dexamethasone and Lenalidomide Chemotherapy Regimen for Multiple Myeloma

Objective:To analyze the effect of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma.Methods:60 cases of multiple myeloma patients admitted to our hospital from January 2022 to December 2023 were selected randomly,with 30 cases in each group.Bortezomib combined with dexamethasone was administered in the control group,and bortezomib combined with dexamethasone and lenalidomide was given to the observation group,and the treatment effect was analyzed.Results:After treatment,CD^(3+)and CD^(4+)of the observation group were higher than that of the control group,CD^(8+)was lower than that of the control group,and the total treatment efficiency was higher,which was statistically significant(P<0.05),and there was no difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bortezomib combined with dexamethasone and lenalidomide is effective in the treatment of multiple myeloma as it regulates the immune function and is safe,thus it can be promoted in clinical practice.

DXM对大鼠星型胶质细胞P53和Bax表达的影响

目的探讨DXM(地塞米松dexamethasone)引起体外纯化培养的大鼠大脑皮质星型胶质细胞凋亡的机制。方法出生1～2 d的新生Wistar大鼠,在无菌条件下取脑,胰蛋白酶消化数分钟,制备星形胶质细胞悬液,以神经胶质纤维酸性蛋白(GFAP)鉴定星形胶质细胞;用不同浓度的DXM(浓度为10-5、10-4、10-3 mol/L)与纯化培养的大鼠大脑皮质星形胶质细胞共同孵育24 h后,用免疫细胞化学方法检测P53、Bax在星型胶质细胞内的表达情况,表达的强弱用平均光密度表示。结果星形胶质细胞的纯度达95%以上,P53和Bax的表达随着DXM浓度的升高而增强,与对照组比较各组均有极显著性差异(P<0.01)。结论上述结果提示P53和Bax的表达增强可能是大剂量DXM引起星型胶质细胞凋亡的主要因素。

地塞米松玻璃体内植入剂治疗糖尿病性黄斑水肿的研究进展

糖尿病性黄斑水肿(DME)作为糖尿病视网膜病变(DR)的严重并发症是一种多因素引起的慢性疾病,炎症因子和血管内皮生长因子(VEGF)在其发展过程中贯穿始终。抗VEGF药物在治疗DME中取得了显著效果,但存在部分患者应答不佳或需要频繁给药等缺点。地塞米松玻璃体内植入剂(DEX植入剂)作为缓释型植入剂有着良好的释放曲线和高效的生物利用度,具有安全、有效且持续的抗炎作用,帮助修复视网膜屏障并减少渗出。为进一步提高患者的视觉质量,探索DEX植入剂与现有治疗方案联合治疗的疗效具有重要临床意义。文章就DEX植入剂的药理特性、适用条件、以及与现有药物和治疗手段联合应用的研究进展进行简要阐述,评估联合或换药治疗相对于现行标准治疗的优劣,以期为DME的个性化治疗选择提供参考。

鹿角多肽调控SLC7A11/GPX4轴抑制地塞米松诱导的成骨细胞铁死亡

背景:激素性股骨头坏死与成骨细胞铁死亡密切相关,鹿角多肽可以通过抑制成骨细胞铁死亡,促进成骨细胞的存活与功能的建立,具有治疗激素性股骨头坏死的潜力,但其对成骨细胞铁死亡的调控机制尚未明确。目的:探究鹿角多肽抑制地塞米松诱导成骨细胞铁死亡的作用机制。方法:①采用不同浓度梯度的鹿角多肽与地塞米松干预MC3T3-E114细胞,CCK-8法检测细胞活性,确定鹿角多肽与地塞米松的作用浓度;②采用不同质量浓度梯度鹿角多肽干预被地塞米松(800μmol/L)处理后的MC3T3-E114细胞,分为空白对照组、地塞米松组、地塞米松+鹿角多肽组,采用CCK-8法计算不同质量浓度鹿角多肽对地塞米松(800μmol/L)干预MC3T3-E114细胞增殖的影响;③借助试剂盒检测空白对照组、地塞米松组、地塞米松+鹿角多肽组中超氧化物歧化酶活性及谷胱甘肽、丙二醛、脂质过氧化物、细胞铁、活性氧含量的变化,并应用Western blot检测谷胱甘肽过氧化物酶4、溶质载体家族7成员11蛋白的表达,验证鹿角多肽抑制铁死亡的通路。结果与结论:①CCK-8法检测细胞活性,结果确定后续实验选择以鹿角多肽(10 mg/mL)和地塞米松(800μmol/L)干预MC3T3-E114细胞处理24 h;②地塞米松干预后,丙二醛、脂质过氧化物、细胞铁、活性氧含量均升高(P<0.01),谷胱甘肽含量、超氧化物歧化酶活性均降低(P<0.01),谷胱甘肽过氧化物酶4、溶质载体家族7成员11蛋白表达降低(P<0.05-0.01);鹿角多肽干预后,上述各指标变化明显被逆转(P<0.05-0.01);③结果表明,鹿角多肽可能通过调控溶质载体家族7成员11/谷胱甘肽过氧化物酶4轴抑制成骨细胞铁死亡,发挥对激素性股骨头坏死的治疗作用。

卵黄蛋白原2对地塞米松诱导肥胖的治疗作用

卵黄蛋白原2(VTG2)被证明可促进3T3-L1脂肪细胞棕色化进程,但其是否能通过促进体内脂肪组织棕色化以治疗肥胖的作用尚未见报道。本试验为探索VTG2对小鼠白色脂肪组织(WAT)棕色化的影响,设置腺相关病毒空载组(AAV9-NC1)和VTG2处理组(AAV9-VTG2),利用苏木精-伊红(H.E.)染色观察WAT脂肪细胞面积大小,免疫组织化学(IHC)染色法、实时荧光定量PCR(qPCR)和蛋白免疫印迹(WB)法检测WAT棕色化标志因子解偶联蛋白-1(UCP1)和过氧化物酶体增殖物激活受体γ共激活剂1-alpha(PGC1α)的表达;为进一步探究VTG2对地塞米松(DEX)诱导的肥胖小鼠中WAT棕色化的影响,设置腺相关病毒空载组(AAV9-NC2组)、DEX处理组(AAV9-NC+DEX组)和VTG2治疗组(AAV9-VTG2+DEX组),采用上述方法检测相同指标。结果显示,与AAV9-NC1组相比,AAV9-VTG2组小鼠腹股沟WAT脂肪细胞面积极显著减小(P<0.01),UCP1和PGC1α的mRNA相对表达量均极显著升高(P<0.001或P<0.01),蛋白相对表达量均显著上调(P<0.01或P<0.05);与AAV9-NC2组相比,AAV9-NC+DEX组小鼠腹股沟WAT脂肪细胞面积极显著增加(P<0.01),UCP1和PGC1α的mRNA相对表达量均极显著降低(P<0.001或P<0.01),蛋白相对表达量均极其显著下调(P<0.001);与AAV9-NC+DEX组相比,AAV9-VTG2+DEX组中小鼠腹股沟WAT脂肪细胞面积极其显著减小(P<0.001),UCP1和PGC1α的mRNA相对表达量均极显著升高(P<0.001或P<0.01),蛋白相对表达量均显著上调(P<0.05)。综上表明,VTG2可促进WAT棕色化,对DEX诱导的肥胖具有抵抗作用,为治疗肥胖提供新的研究思路。

骨髓间充质干细胞来源的外泌体抑制地塞米松诱导的C2C12肌管萎缩

目的研究骨髓间充质干细胞(bone marrow mesenchymal stem cells,BMSCs)来源的外泌体(exsomes,EXOs)对地塞米松(dexamethasone,DEX)诱导的C2C12肌管萎缩的影响。方法(1)分离提取培养C57BL/6J小鼠BMSCs。(2)提取并鉴定BMSCs-EXOs。(3)C2C12细胞成肌分化。(4)将肌管细胞分为对照组(Control,2%马血清培养基培养48 h)、地塞米松组(DEX、浓度为10μmol·L^(-1)的DEX干预肌管48 h)、外泌体组(EXOs、外泌体干预肌管48 h)、外泌体抑制剂组(GW4869、10μmol的GW4869干预BMSCs后提取的外泌体干预肌管48 h)。48 h后测量各组肌管直径,CCK-8法检测各组细胞活力,Western blot检测各组肌肉萎缩及成肌分化相关蛋白的表达量。结果BMSCs呈长梭形,BMSCs-EXOs在透射电镜下为圆形的双层膜结构,直径约200 nm,且高表达CD9、CD63和CD81。相比于Control组,DEX组细胞活性降低(P<0.01),肌管细胞直径减少(P<0.01),atrogin-1(P<0.05)和MuRF-1(P<0.01)的表达明显上调,MYOD(P<0.01)蛋白表达降低;相比于DEX组,BMSCs-EXOs组细胞活性升高(P<0.01),肌管细胞直径增加(P<0.01),atrogin-1(P<0.05)和MuRF-1(P<0.01)的表达明显下调,MYOD(P<0.01)蛋白表达升高;相比于BMSCs-EXOs组,BMSCs-EXOs(GW4869)组细胞活性降低(P<0.05),肌管细胞直径减少(P<0.01),atrogin-1(P<0.05)和MuRF-1(P<0.05)的表达上调,MYOD(P<0.01)蛋白表达降低。结论骨髓间充质干细胞来源的外泌体(BMSCs-EXOs)可抑制地塞米松诱导的C2C12肌管萎缩。

PC与DXM-PC支架治疗不稳定性心绞痛的对照研究

目的比较普通磷酸胆碱涂层(phosphorytcholine,PC)支架与可释放地塞米松的磷酸胆碱涂层(dexamethasone-phosphorytcholine,DXM-PC)支架治疗具有冠状动脉单支病变的不稳定性心绞痛的长期临床效果。方法将入组的120例不稳定性心绞痛患者随机分入两组,分别植入两种不同支架。一组为PC支架治疗组(n=60),以下简称PC组;另一组为DXM-PC支架(n=60),以下简称DXM-PC组。观察两组患者术后4年的主要心血管不良事件的发生率。结果所有患者均成功植入支架,在支架植入术后4年,DXM-PC组与PC组相比,具有更低的主要心血管不良事件发生率。结论在治疗具有原发冠状动脉单支病变的不稳定性心绞痛患者时,DXM-PC支架安全,较之PC支架能更有效地防止主要心血管不良事件的发生,从而获得更好的长期临床效果。

Observation on Apoptosis of Erythroid Cells Induced by Dexamethasone

Using splenic cells of BALB/c mice infected with Friend Leukemia Virus (FVA) as a model of erythroid cells, we investigated the action of dexamethasone (Dex) to induce apoptosis of the cells in the presence of erythropoietin (EPO)——an apoptotic inhibitor in developing erythroid cells. The result indicated that after treatment with a certain range of Dex concentrations and prolonged incubation, the cells were characterized by the occurrence of DNA ladders which appeared on agarose electrophoresis. Transmission electron microscopy showed that karyopyknosis, chromatin condensation, dilatation of the perinuclear space, karyorrhexis, cytoplasmic vacuolization and cell fragmentation appeared in the cells depending on the dose of Dex and the treatment time. These results suggest that Dex could induce apoptosis in the developing erythroid cells as in other cells so far reported.

藏药秦艽花黄酮对DXMS模型小鼠红细胞免疫功能的影响

旨在探究藏药秦艽花黄酮对小鼠红细胞免疫功能的影响,为藏药开发利用奠定理论基础.以乙醇回流提取的秦艽花总黄酮为研究材料,DXMS(地塞米松)小鼠(免疫抑制模型)为研究对象,RBC-C3bRR、RBC-ICR、RBC-C3bER、RBC-C3bIR、RBC-C3bMφ、DTER为研究手段,红细胞C3b受体活性、红细胞免疫复合物花环率、血清红细胞免疫调节促进/抑制因子活性、吞噬细胞的吞噬作用和肿瘤细胞花环率为检测指标,探讨藏药秦艽花总黄酮对红细胞免疫功能的影响.结果表明,连续注射7~14 d DXMS,小鼠红细胞免疫功能低下,给予藏药秦艽花总黄酮(生药浓度100%、总黄酮浓度24.4 mg/mL)7~14 d后,小鼠红细胞C3b受体活性增强,对DXMS引起的DTER下降具有拮抗作用,且生药浓度50%~100%(黄酮浓度12.2~24.4 mg/mL)具有增强促进因子活性和降低抑制因子活性的作用,同时提高DXMS致使巨噬细胞低下的吞噬百分率和吞噬指数.表明藏药秦艽花总黄酮(12.2~24.4 mg/mL)具有促进红细胞免疫粘附功能和增强吞噬细胞吞噬功能的作用.